|EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer—2020 update. Part 1: screening, diagnosis, and local treatment with curative intent|
N Mottet, RCN van den Bergh, E Briers, T Van den Broeck, ...
European urology 79 (2), 243-262, 2021
|Abiraterone for prostate cancer not previously treated with hormone therapy|
ND James, JS de Bono, MR Spears, NW Clarke, MD Mason, ...
New England Journal of Medicine 377 (4), 338-351, 2017
|Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up|
B Escudier, C Porta, M Schmidinger, N Rioux-Leclercq, A Bex, V Khoo, ...
Annals of Oncology 30 (5), 706-720, 2019
|Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial|
CC Parker, ND James, CD Brawley, NW Clarke, AP Hoyle, A Ali, ...
The Lancet 392 (10162), 2353-2366, 2018
|European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I|
S Krege, J Beyer, R Souchon, P Albers, W Albrecht, F Algaba, M Bamberg, ...
European urology 53 (3), 478-496, 2008
|EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II—2020 update: treatment of relapsing and metastatic prostate cancer|
P Cornford, RCN van den Bergh, E Briers, T Van den Broeck, ...
European urology 79 (2), 263-282, 2021
|Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells|
E Scandella, Y Men, S Gillessen, R Forster, M Groettrup
Blood, The Journal of the American Society of Hematology 100 (4), 1354-1361, 2002
|Mouse interleukin‐12 (IL‐12) p40 homodimer: a potent IL‐12 antagonist|
S Gillessen, D Carvajal, P Ling, FJ Podlaski, DL Stremlo, PC Familletti, ...
European journal of immunology 25 (1), 200-206, 1995
|Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up|
C Parker, E Castro, K Fizazi, A Heidenreich, P Ost, G Procopio, B Tombal, ...
Annals of Oncology 31 (9), 1119-1134, 2020
|Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up|
C Parker, S Gillessen, A Heidenreich, A Horwich
Annals of Oncology 26, v69-v77, 2015
|Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017|
S Gillessen, G Attard, TM Beer, H Beltran, A Bossi, R Bristow, B Carver, ...
European urology 73 (2), 178-211, 2018
|Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand|
N Mach, S Gillessen, SB Wilson, C Sheehan, M Mihm, G Dranoff
Cancer research 60 (12), 3239-3246, 2000
|Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augmentsá…|
R Soiffer, FS Hodi, F Haluska, K Jung, S Gillessen, S Singer, K Tanabe, ...
Journal of clinical oncology 21 (17), 3343-3350, 2003
|Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015|
S Gillessen, A Omlin, G Attard, JS De Bono, E Efstathiou, K Fizazi, ...
Annals of Oncology 26 (8), 1589-1604, 2015
|Rapid mass spectrometric conversion of tissue biopsy samples into permanent quantitative digital proteome maps|
T Guo, P Kouvonen, CC Koh, LC Gillet, WE Wolski, HL R÷st, ...
Nature medicine 21 (4), 407-413, 2015
|Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review|
T Van den Broeck, RC Van Den Bergh, N Arfi, T Gross, L Moris, E Briers, ...
European urology 75 (6), 967-987, 2019
|Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019|
S Gillessen, G Attard, TM Beer, H Beltran, A Bjartell, A Bossi, A Briganti, ...
European urology 77 (4), 508-547, 2020
|Addition of docetaxel to hormonal therapy in low-and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial|
NW Clarke, A Ali, FC Ingleby, A Hoyle, CL Amos, G Attard, CD Brawley, ...
Annals of Oncology 30 (12), 1992-2003, 2019
|Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer|
J Beyer, P Albers, R Altena, J Aparicio, C Bokemeyer, J Busch, ...
Annals of oncology 24 (4), 878-888, 2013
|Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial|
F Saad, J Carles, S Gillessen, A Heidenreich, D Heinrich, J Gratt, J LÚvy, ...
The Lancet Oncology 17 (9), 1306-1316, 2016